Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States.
+ 2 more risks
Adequate balance sheet and overvalued.
Share Price & News
How has Aileron Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 015's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 015 underperformed the German Biotechs industry which returned -5.1% over the past year.
Return vs Market: 015 underperformed the German Market which returned -17.5% over the past year.
Price Volatility Vs. Market
How volatile is Aileron Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Aileron Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 015's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 015's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 015 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 015 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 015's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 015 is good value based on its PB Ratio (0.4x) compared to the DE Biotechs industry average (3.6x).
How is Aileron Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 015 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 015 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 015 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if 015's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if 015's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 015's Return on Equity is forecast to be high in 3 years time
How has Aileron Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 015 is currently unprofitable.
Growing Profit Margin: 015 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 015 is unprofitable, and losses have increased over the past 5 years at a rate of -20.7% per year.
Accelerating Growth: Unable to compare 015's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 015 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: 015 has a negative Return on Equity (-127.84%), as it is currently unprofitable.
How is Aileron Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: 015's short term assets ($26.5M) exceed its short term liabilities ($6.4M).
Long Term Liabilities: 015's short term assets ($26.5M) exceed its long term liabilities ($4.7M).
Debt to Equity History and Analysis
Debt Level: 015 is debt free.
Reducing Debt: 015 has not had any debt for past 5 years.
Inventory Level: 015 has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 015's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 015 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 015 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Aileron Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 015's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 015's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 015's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 015's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 015's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Alves Aivado (49yo)
Dr. Manuel C. Aivado, also known as Alves, M.D., Ph.D., has been President, Chief Executive Officer and Director of Aileron Therapeutics, Inc. since September 6, 2018. Dr. Aivado served as Chief Medical Of ...
CEO Compensation Analysis
Compensation vs Market: Alves's total compensation ($USD1.46M) is above average for companies of similar size in the German market ($USD432.27K).
Compensation vs Earnings: Alves's compensation has been consistent with company performance over the past year.
|Senior VP & Chief Medical Officer||1.33yrs||US$760.04k||0.27% $24.4k|
|SVP, CFO & Treasurer||0.50yr||no data||no data|
|Senior Vice President of Research||1.33yrs||no data||0.027% $2.5k|
|Senior VP & Chief Business Officer||1yr||no data||0.16% $14.6k|
Experienced Management: 015's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|Director||0.75yr||no data||0.78% $71.0k|
|Director||0.75yr||no data||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
|Member of Advisory Board||12.42yrs||no data||no data|
|Lead Director||2yrs||US$109.35k||no data|
|Chairman of Scientific Advisory Board||no data||no data||no data|
|Member of Advisory Board||no data||no data||no data|
|Chairman of Scientific Advisory Board||no data||no data||no data|
|Chairman of the Board||2yrs||US$214.31k||0.27% $24.4k|
Experienced Board: 015's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.1%.
Aileron Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Aileron Therapeutics, Inc.
- Ticker: 15
- Exchange: DB
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$10.037m
- Listing Market Cap: US$9.052m
- Shares outstanding: 27.81m
- Website: https://www.aileronrx.com
Number of Employees
- Aileron Therapeutics, Inc.
- 490 Arsenal Way
- Suite 210
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|15||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2017|
|ALRN||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Jun 2017|
Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company’s lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/30 00:19|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.